지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.12
- 수록면
- 322 - 331 (10page)
- DOI
- 10.5045/br.2021.2021101
이용수
초록· 키워드
오류제보하기
Background In this retrospective cohort of patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis, 57 patients with MF who received ruxolitinib for MF-related symptoms or symptomatic splenomegaly were evaluated.
Methods The median age of the patients in this cohort was approximately 58 years. Of these, there were 33 patients (57.9%) in INT-1, 23 patients (40.4%) in INT-2, and 1 patient (1.8%) at high risk. Overall, spleen size reduction of at least 35% (spleen response) was achieved in 56.6% and 63.3% of all cohort and INT-1 risk at any time, respectively.
Results Symptom response and clinical improvement were observed in 21.7% and 60.7% of patients, respectively. Anemia and thrombocytopenia were prevalent, but manageable.
About 73.7% of patients continued treatment during a median follow-up of 22 months.
Two-year OS probability was approximately 84.5% (95% CI, 63.1?94.0%) and 62.3% (95% CI, 37.5?79.6%) for the intermediate-1 and -2 risk groups, respectively.
Conclusion Real-life experience in a community-based hospital confirms the efficacy and safety profile of ruxolitinib in intermediate-risk myelofibrosis. Treatment discontinuation rates were lower than those in clinical trials.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Cervantes F / 2014 / How I treat myelofibrosis / Blood 124:2635~2642
Passamonti F / 2010 / A dynamic prognostic model to predict survival in primary myelofibrosis : a study by the IWG-MRT(International Working Group for Myeloproliferative Neoplasms Research and Treatment) / Blood 115:1703~1708
Gangat N / 2011 / DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status / J Clin Oncol 29:392~397
Guglielmelli P / 2018 / MIPSS70 : Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis / J Clin Oncol 36:310~318
Tefferi A / 2018 / MIPSS70+ Version 2.0:Mutation and Karyotype-Enhanced International Prognostic Scoring System for primary myelofibrosis / J Clin Oncol 36:1769~1770
Passamonti F / 2010 / A dynamic prognostic model to predict survival in primary myelofibrosis : a study by the IWG-MRT(International Working Group for Myeloproliferative Neoplasms Research and Treatment) / Blood 115:1703~1708
Gangat N / 2011 / DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status / J Clin Oncol 29:392~397
Guglielmelli P / 2018 / MIPSS70 : Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis / J Clin Oncol 36:310~318
Tefferi A / 2018 / MIPSS70+ Version 2.0:Mutation and Karyotype-Enhanced International Prognostic Scoring System for primary myelofibrosis / J Clin Oncol 36:1769~1770
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Ruxolitinib and Severe COVID-19
Infection and Chemotherapy
2021 .12
-
Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis
Infection and Chemotherapy
2021 .09
-
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib
Annals of Dermatology
2019 .01
-
Ruxolitinib-induced extreme thrombocytosis in a COVID-19 patient
Blood Research
2021 .09
-
단일 기관 내 Steroid-Refractory Graft-versus-Host Disease 환자에서의 Ruxolitinib 반응성 평가
병원약사회지
2023 .05
-
A Rare Case of Primary Myelofibrosis With a Solitary 1q Triplication
Annals of Laboratory Medicine
2020 .01
-
Primary Idiopathic Myelofibrosis: Clinico-Epidemiological Profile and Risk Stratification in Pakistani Patients
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Extranasal natural killer/T-cell lymphoma initially presenting as myelofibrosis
Blood Research
2016 .01
-
골수섬유증 치료의 발전
대한내과학회지
2016 .01
-
Novel therapeutics for myelofibrosis
Blood Research
2023 .04
-
A Pediatric Case of Atypical Chronic Myeloid Leukemia with CSF3R Mutation Not Responding to Ruxolitinib, but Rescued by Allogeneic Transplantation
Clinical Pediatric Hematology-Oncology
2021 .10
-
Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm
Blood Research
2022 .03
-
JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Prognostication in myeloproliferative neoplasms, including mutational abnormalities
Blood Research
2023 .04
-
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Clinical Efficacy and Safety of Endoscopic Treatment of Gastrointestinal Stromal Tumors in the Stomach
Gut and Liver
2023 .03
-
Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor
Journal of Gynecologic Oncology
2020 .01
-
진성적혈구증가증/본태성혈소판증가증 치료의 발전
대한내과학회지
2016 .01
-
Role of systematic lymphadenectomy in patients with intermediate to high- risk early stage endometrial cancer
Journal of Gynecologic Oncology
2023 .05
-
골수증식종양 진단의 발전
대한내과학회지
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0